Denali Therapeutics Inc.
Income Statement
| Line Item | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $294.1M | $35.1M | $10.3M | $3.6M | $52.5M | $42.1M | $12.5M | $5.3M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $97.5M | $128.8M | $92.1M | $87.8M | $92.7M | $86.1M | $67.9M | $71.6M |
| SG&A Expense | $26.1M | $27.1M | $23.5M | $23.3M | $21.2M | $22.5M | $21.8M | $19.3M |
| Operating Income | $170.5M | $-120.8M | $-105.3M | $-107.5M | $-61.4M | $-66.5M | $-77.1M | $-85.6M |
| Operating Margin | 58.0% | -343.8% | -1,024.4% | -3,020.1% | -117.0% | -157.8% | -616.3% | -1,619.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | $0 | — | — | $0 | $27.0K | — | $-575.0K | $0 |
| Net Income | $183.4M | $-109.8M | $-98.7M | $-103.3M | $-58.8M | $-65.2M | $-75.3M | $-84.6M |
| Net Margin | 62.3% | -312.4% | -959.6% | -2,902.5% | -112.0% | -154.8% | -601.4% | -1,600.5% |
| EPS (Basic) | $1.34 | $-0.80 | $-0.75 | $-0.84 | $-0.48 | $-0.53 | $-0.62 | $-0.69 |
| EPS (Diluted) | $1.30 | $-0.80 | $-0.75 | $-0.84 | $-0.48 | $-0.53 | $-0.62 | $-0.69 |
| Shares Outstanding (Basic) | 137.0M | 136.5M | 125.5M | 123.5M | 123.0M | 122.7M | 121.5M | 121.7M |
| Shares Outstanding (Diluted) | 140.9M | 136.5M | 125.5M | 123.5M | 123.0M | 122.7M | 121.5M | 121.7M |
| Dividends Per Share | — | — | — | — | — | — | — | — |